Activate map
Yes |
Specialties
The Neuropsychology Clinic is owned by Dr. Samuel D. Brinkman, Ph.D. He is the only neuropsychologist in the Abilene area.
Dr. Brinkman and his colleagues work with patients who have specific disorders in structure or function of the brain as they relate to psychological processes and behaviors. The Neuropsychology Clinic specializes in neuropsychological testing for a variety of reasons and Dr. Brinkman specializes in Alzheimer’s disease and other dementias.
Dr. Brinkman received his Ph. D in 1980 from the University of Houston and has been in private practice for over 20 years. He serves on various boards including the North Central Texas Chapter Alzheimer’s Association, Serenity Foundation and Kenley School.
Dr. Brinkman is currently hosting a radio show on Voice America: Health and Wellness entitled «NeuroMatters: The Brink of Alzheimer’s.» It airs every Tuesday.
History
Established in 1984.
Samuel D. Brinkman, Ph. D, is president of Dementia Screening, Inc., and lead developer of the easy-to-use dementia screening tool, The GrayMatters® Assessment System. Dr. Brinkman is a neuropsychologist who has spent more than 30 years in the evaluation and treatment of individuals with Alzheimer’s Disease and other dementias.
He felt strongly that there was a need for a screening system that would be both accurate and cost effective in identifying the earliest symptoms of Alzheimer’s disease After more than eight years of research and development, Dr. Brinkman and a team of other professionals created The GrayMatters® Assessment System.
Meet the Business Owner
Dr. Samuel B.
Business Owner
Dr. Brinkman is currently in private practice in Abilene, Texas, and serves as an adjunct faculty member at Abilene Christian University and Hardin-Simmons University. He served in Vietnam in U.S. Army Intelligence, received his bachelor’s of science degree from the University of Texas at El Paso and his master’s and doctoral degrees from the University of Houston
Dr. Brinkman spent several years in the evaluation of medications developed for Alzheimer’s disease. He maintains an active interest in Alzheimer’s treatment and in head injury care, having chaired numerous boards and committees on both local and national levels.